BeOne Medicines Beats Q3 2026 Estimates as Revenue Rises 34% to $1.89B
Revenue of $1.89B vs. $1.76B expected and adjusted EPS of $4.59 vs. $1.90; revenue up 34% from a year earlier.
BeOne Medicines (ONC) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $1.89 billion, up 34% from a year earlier, above the $1.76 billion estimate, and adjusted EPS was $4.59, up 321% from a year earlier, above the $1.90 estimate.
Shares rose 5.9% in premarket trading as of 6:31 a.m. ET, to $400.00 from a $377.78 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | $1.90 | $4.59 | Beat by 142% |
| Revenue | $1.76B | $1.89B | Beat by 7.5% |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▲ 321% | ▲ 124% |
| Revenue | ▲ 34% | ▲ 11% |
By our calculation, revenue was $131.5 million above the estimate and adjusted EPS was $2.69 above it. The QoQ column compares with the previous quarter's revenue of $1.71 billion and adjusted EPS of $2.05. The YoY column compares with $1.41 billion and $1.09 in the same quarter a year earlier.
GAAP results
- GAAP EPS. GAAP diluted EPS was $42.64, against $13.52 a year earlier.
- Net income. The company reported net income of $384.7 million on a GAAP basis, compared with net income of $124.8 million a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 6 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 5 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $1.41 billion, $1.50 billion, $1.51 billion, $1.71 billion and $1.89 billion.
What to watch
- Next-quarter estimates. Consensus calls for EPS of $1.64 and revenue of $1.79 billion next quarter, based on 6 analysts.
- Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 34% increase to $1.89 billion.
- Estimate record. Whether BeOne Medicines extends a record of beating EPS estimates in 6 of its last 8 reports.
- Related coverage. See our reports on NewAmsterdam Pharma, Advanced Drainage Systems, Americold Realty Trust and Agios Pharmaceuticals.
Sources: Results are from BeOne Medicines's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from BeOne Medicines's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
NewAmsterdam Pharma Beats Q3 2026 Estimates as Revenue Rises 5407% to $19.2M
EarningsAdvanced Drainage Systems Fiscal Q2 2027 EPS Tops Estimates at $1.88, but Revenue Misses at $889.4M
EarningsAmericold Realty Trust Beats Q3 2026 Estimates as Revenue Rises 4.2% to $691.6M
EarningsAgios Pharmaceuticals Beats Q3 2026 Estimates as Revenue Rises 330% to $55.4M
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.